• 提示：詳情請下載說明書。

• 產(chǎn)品描述： Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.

• 靶點(diǎn)： PI3Kα:19 nM (IC50);PI3Kβ:54 nM (IC50);PI3Kδ:39 nM (IC50);PI3Kγ:311 nM (IC50);HDAC1:1.7 nM (IC50);HDAC2:5 nM (IC50);HDAC3:1.8 nM (IC50);HDAC4:409 nM (IC50);HDAC5:674 nM (IC50);HDAC6:27 nM (IC50);HDAC7:426 nM (IC50);HDAC8:191 nM (IC50);HDAC9:554 nM (IC50);HDAC10:2.8 nM (IC50);HDAC11:5.4 nM (IC50);Apoptosis;PI3K;HDAC

• 體內(nèi)研究：
  Oral administration of Fimepinostat inhibits growth of the Daudi cancer cell xenografts in a dose-dependent manner. Tumor stasis is observed at 100 mg/kg in this model without obvious toxicity. Importantly, in the same model, Fimepinostat achieves better efficacy than GDC-0941, SAHA, or a combination of these 2 compounds given at their maximal tolerated doses (MTD). Furthermore, Fimepinostat causes tumor regression or stasis after intravenous (50 mg/kg) or oral administration (100 mg/kg) in a xenograft tumor model of SU-DHL4 diffuse large B-cell lymphoma (DLBCL) and causes tumor stasis in KRAS-mutant A549 NSCLC cell xenografts

• 參考文獻(xiàn)：
  1. Qian C, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res. 2012 Aug 1;18(15):4104-13.

• 溶解性： DMSO  :  50  mg/mL  (98.32  mM;  Need  ultrasonic)    DMF  :  5  mg/mL  (9.83  mM;  Need  ultrasonic)

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	1.966 ml	9.832 ml	19.664 ml
  5 mM	0.393 ml	1.966 ml	3.933 ml
  10 mM	0.197 ml	0.983 ml	1.966 ml
  50 mM	0.039 ml	0.197 ml	0.393 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *